Lavipharm S.A (LAVI.AT) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · Greece · ISIN GRS246073001
Lavipharm S.A financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 52.95 m EUR | 62.58 m EUR |
| Gross profit | 25.08 m EUR | 30.31 m EUR |
| Operating income | 5.47 m EUR | 9.01 m EUR |
| EBIT | 5.62 m EUR | 9.34 m EUR |
| Net income | 8.98 m EUR | 5.99 m EUR |
| Diluted EPS – continuing operations | 0.05 EUR | 0.04 EUR |
Full history since 2002, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Lavipharm S.A
Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; and over the counter (OTC) drugs, such as antiseptics, anagelsics, and anti-lice treatment products. It also provides a range of skincare products focused on health. The company was founded in 1911 and is based in Paiania, Greece.
More stocks
- Track & Field Co S.A (TFCO4.SA)
- Profile Systems & Software SA (PROF.AT)
- Bauer (B5A0.HM)
- Gurit Holding AG (GURN.SW)
- Neuberger Berman IMF Inc (NBH)
- Modern Avenue Group Co Ltd (002656.SZ)
- Agencia Comercial Spirits Ltd Class A Ordinary Shares (AGCC)
- AIM Industrial Growth Freehold and Leasehold Real Estate Investment Trust (AIMIRT.BK)
- Diamond Food Indonesia PT (DMND.JK)
- Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126.SZ)
- Rex Concepts S.A. (REX.WA)
- Heilongjiang Interchina Water Treatment Co Ltd (600187.SS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.